Search the name of an FDA-approved drug and you expect the first page of results to agree on what it is. Search tesamorelin and the top results hand you three different daily figures, stated with equal confidence. None of them describes the product a United States pharmacy actually ships today.
The interesting part is that almost none of those numbers are invented. They are expired. Tesamorelin's approved daily dose has been revised twice in fifteen years, each revision attached to a different formulation, and the current prescribing information states in plain language that the formulations are not substitutable. A page quoting the 2010 figure is not lying. It is describing a product that stopped being the product.
So the lesson here is not the tired one about checking your sources. It is narrower and more useful. For a drug that exists in more than one concentration, a number with no formulation name and no year attached is worse than no number at all: it looks like information and behaves like noise.
The label has said three different things
Tesamorelin received its initial United States approval in 2010, as Egrifta, for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That original formulation carried a labeled dose of 2 mg once daily by subcutaneous injection.
In 2019 the FDA approved a reformulated single-vial version, Egrifta SV, with a labeled dose of 1.4 mg once daily, drawn as 0.35 mL of reconstituted solution. Different number, same molecule, same indication.
On 25 March 2025 the FDA approved the F8 formulation, commercialised as Egrifta WR, with a labeled dose of 1.28 mg once daily, drawn as 0.16 mL. It is eight times more concentrated than the 2010 product and twice as concentrated as Egrifta SV, and it is reconstituted weekly rather than daily. Theratechnologies announced availability through specialty pharmacies on 5 September 2025, and Egrifta WR is gradually replacing Egrifta SV as coverage transfers.
Through all of it the indication never moved. Tesamorelin remains the only medication approved in the United States for reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The Egrifta SV label is explicit that the drug is not indicated for weight loss management and has a weight-neutral effect, a sentence worth reading twice given how the molecule gets discussed online.
The sentence nobody quotes is the one that matters
Sitting in the current prescribing information is this: there are two Egrifta formulations, they carry different recommended dosages, and they are not substitutable.
That single line is what turns a stale citation from a trivia error into a clinically meaningful one.
It is the most underrated sentence in the entire public tesamorelin literature, and it appears in roughly none of the pages that rank for the drug's name. A reader who lands on a 2019-accurate page in September 2026 is not reading an approximation of the truth. They are reading the specification of a different product, presented with total confidence and no timestamp.
The pages that rank were built to be found, not to be updated
I went through the top results the way a fact-checker would, and the picture is more interesting than the usual complaint about content farms.
One of them, peptidedosingprotocols.com, is the most careful of the group. It separates approved from off-label use, repeats that tesamorelin is FDA-approved only for HIV-associated lipodystrophy, carries an explicit not-medical-advice disclaimer, and lists twelve numbered references including the LIPO-010 programme and Stanley's 2019 work in Lancet HIV. It also carries affiliate links to peptide suppliers, complete with a discount code and a commission disclosure. Both things are true at the same time.
Another, guidetopeptide.com, states the 2010 figure and the 2019 figure, prices the drug at roughly $24,000 to $30,000 per year, and cites no primary sources whatsoever. Its disclaimer is the supplement-industry boilerplate about claims not having been evaluated by the FDA, which is a peculiar thing to print on a page about a biologic the FDA approved sixteen years ago.
Then there is the query that actually pays. Pages titled "Where to buy tesamorelin in 2026" and "How to get tesamorelin in 2026" rank comfortably alongside the explainers. As intent moves from informational to transactional, citation quality falls and commercial interest rises. That is not a conspiracy. It is an incentive gradient, and it runs through every molecule in this category.
I do not think the fix is to attack these pages. Two of the three disclose their commercial relationships more openly than a good deal of mainstream health media does. The fix is dating. Not one of them tells you which label year you are reading.
The regulatory silence underneath
Tesamorelin occupies an odd position. It is an approved biologic with a listed company behind it, and simultaneously a name that circulates freely in the research-use-only grey market.
Compare it with what happened on 23 and 24 July 2026, when the Pharmacy Compounding Advisory Committee voted on candidates for the 503A Bulks List. BPC-157, KPV and TB-500 passed 8-6 with one abstention. MOTS-c passed 7-5 with two abstentions. Epitalon and Semax also went through, emideltide did not, and the FDA's own scientists argued against. Even so, the agency is not bound by the recommendation, formal rulemaking is required, and HHS has not acted, so nothing about that vote settled the legal question.
Tesamorelin was not on that ballot, and it did not need to be. Approved drugs raise a different compounding question entirely, the one about copies of approved products. And since 7 January 2025 the FDA has stopped assigning interim categories to newly nominated bulk substances, which narrowed the informal corridor in which the grey market used to describe itself as merely unresolved.
The practical consequence deserves to be said flatly. For most people looking this drug up, tesamorelin's public information environment is governed by search ranking, not by any agency.
The strongest objection, and why it does not hold
The fair counter-argument is that none of this matters much, because anyone actually prescribed the drug receives the prescribing information in the box, and the people reading peptide blogs were never getting a prescription anyway.
Two problems with that. The first is timing. The changeover between two non-substitutable formulations is happening right now, in the middle of a coverage shift, after a manufacturing disruption that cut reported Egrifta SV sales 31.3% to $11.1 million in the second quarter of 2025, against first-quarter revenue of $19 million with Egrifta sales up 45%, and full-year 2025 guidance of $80 million to $83 million. Patients moving from one formulation to another are precisely the population most likely to type the drug's name into a search box between appointments.
The second problem is the other readership. The people with no label at all are the ones relying entirely on these pages, and they are the group for whom an undated number does the most damage. Telling them to consult a clinician is correct and insufficient. Publishing dated, sourced, formulation-specific facts is the part a magazine can actually do.
What a fact-check is for
This piece is not an argument that one of those three figures is the right one to act on. It is an argument that the question "what is the tesamorelin dose" has no answer at all without two qualifiers, and that every page answering it without them is producing confident noise.
Ozemback does not tell anyone what to take, and will not. What an independent publication can do, and what almost nobody in this category bothers to do, is attach a date and a formulation to every number it prints, and say plainly when the label moved underneath a claim that is still ranking.
Ozemback, September 2026